Search Results

Display Settings
Results per page: 10
Sort By: Relevance
Filter
  • 1-10 of  17,024 results for ""Drug Substitution""

Your Filters

Reset filters
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

Can we predict the risk factors for switching due to ineffectiveness in the first year of therapy with bDMARD in patients with rheumatoid arthritis?

  • Authors : Martins A; Rheumatology Department, Centro Hospitalar Universitário São João, Porto, Portugal. Electronic address: .; Pimenta S

Subjects: Arthritis, Rheumatoid*/Arthritis, Rheumatoid*/Arthritis, Rheumatoid*/drug therapy ; Arthritis, Rheumatoid*/Arthritis, Rheumatoid*/Arthritis, Rheumatoid*/complications ; Antirheumatic Agents*/Antirheumatic Agents*/Antirheumatic Agents*/therapeutic use

  • Source: Reumatologia clinica [Reumatol Clin (Engl Ed)] 2024 Aug-Sep; Vol. 20 (7), pp. 380-385.Publisher: Elsevier Doyma Country of Publication: Spain NLM ID: 101717526 Publication Model: Print Cited Medium: Internet ISSN: 2173-5743

Record details

Read More Add to Saved list
×
Academic Journal

Outcomes following switching from etanercept originator to etanercept biosimilar in 1024 patients with RA: a matched-analysis of the BSRBR-RA.

Subjects: Etanercept*/Etanercept*/Etanercept*/therapeutic use ; Biosimilar Pharmaceuticals*/Biosimilar Pharmaceuticals*/Biosimilar Pharmaceuticals*/therapeutic use ; Biosimilar Pharmaceuticals*/Biosimilar Pharmaceuticals*/Biosimilar Pharmaceuticals*/economics

  • Source: Rheumatology (Oxford, England) [Rheumatology (Oxford)] 2024 Aug 01; Vol. 63 (8), pp. 2082-2092.Publisher: Oxford University Press Country of Publication: England NLM ID: 100883501 Publication Model: Print Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Risk Factors for Meeting Criteria for Switching from Bevacizumab to Aflibercept When Treating Eyes with Diabetic Macular Edema and Visual Acuity of < 20/40.

Subjects: Receptors, Vascular Endothelial Growth Factor*/Receptors, Vascular Endothelial Growth Factor*/Receptors, Vascular Endothelial Growth Factor*/therapeutic use ; Recombinant Fusion Proteins*/Recombinant Fusion Proteins*/Recombinant Fusion Proteins*/therapeutic use ; Recombinant Fusion Proteins*/Recombinant Fusion Proteins*/Recombinant Fusion Proteins*/administration & dosage

  • Source: Ophthalmology [Ophthalmology] 2024 Aug; Vol. 131 (8), pp. 967-974. Date of Electronic Publication: 2024 Feb 08.Publisher: Elsevier Country of Publication: United States NLM ID: 7802443 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patient with chronic hepatitis B.

  • Authors : Nam H; The Catholic University Liver Research Center, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.; Division of Hepatology, Department of Internal Medicine, Uijeongbu St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Bucheon-si, Republic of Korea.

Subjects: Tenofovir*/Tenofovir*/Tenofovir*/therapeutic use ; Tenofovir*/Tenofovir*/Tenofovir*/administration & dosage ; Tenofovir*/Tenofovir*/Tenofovir*/adverse effects

  • Source: Journal of gastroenterology and hepatology [J Gastroenterol Hepatol] 2024 Aug; Vol. 39 (8), pp. 1673-1683. Date of Electronic Publication: 2024 May 01.Publisher: Blackwell Scientific Publications Country of Publication: Australia NLM ID: 8607909 Publication Model: Print-Electronic Cited Medium:

Record details

Read More Add to Saved list
×
Academic Journal

ARE WE READY FOR MULTIPLE SWITCHES BETWEEN REFERENCE PRODUCTS AND BIOSIMILARS?

Subjects: Biosimilar Pharmaceuticals*/Biosimilar Pharmaceuticals*/Biosimilar Pharmaceuticals*/therapeutic use ; Inflammatory Bowel Diseases*/Inflammatory Bowel Diseases*/Inflammatory Bowel Diseases*/drug therapy ; Drug Substitution*

  • Source: Arquivos de gastroenterologia [Arq Gastroenterol] 2024 Jul 19; Vol. 61, pp. e24046. Date of Electronic Publication: 2024 Jul 19 (Print Publication: 2024).Publisher: Instituto Brasileiro de Estudos e Pesquisas de Gastroenterologia Country of Publication: Brazil NLM ID: 15310600R Publication Model: eCollection

Record details

Read More Add to Saved list
×
Academic Journal

Effectiveness of Switching to Subcutaneous Infliximab in Ulcerative Colitis Patients Experiencing Intravenous Infliximab Failure.

  • Authors : Bae JH; Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.; Park JB

Subjects: Colitis, Ulcerative*/Colitis, Ulcerative*/Colitis, Ulcerative*/drug therapy ; Infliximab*/Infliximab*/Infliximab*/administration & dosage ; Infliximab*/Infliximab*/Infliximab*/pharmacokinetics

  • Source: Gut and liver [Gut Liver] 2024 Jul 15; Vol. 18 (4), pp. 667-676. Date of Electronic Publication: 2024 Jun 05.Publisher: Editorial Office of Gut and Liver Country of Publication: Korea (South) NLM ID: 101316452 Publication Model: Print-Electronic Cited Medium:

Record details

Read More Add to Saved list
×
Academic Journal

Systematic review: effectiveness and safety of switching between originator infliximab and biosimilar infliximab in patients with inflammatory bowel disease.

  • Authors : Lichtenstein GR; Department of Internal Medicine, Perelman School of Medicine of the University of Pennsylvania, Philadelphia, PA, USA.; Soonasra A

Subjects: Infliximab*/Infliximab*/Infliximab*/adverse effects ; Infliximab*/Infliximab*/Infliximab*/therapeutic use ; Infliximab*/Infliximab*/Infliximab*/administration & dosage

  • Source: Expert opinion on biological therapy [Expert Opin Biol Ther] 2024 Jul; Vol. 24 (7), pp. 691-708. Date of Electronic Publication: 2024 Jul 18.Publisher: Taylor & Francis Country of Publication: England NLM ID: 101125414 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Reasons for switching oral antipsychotic medications and related patterns of care and costs in patients with schizophrenia initiating monotherapy treatment: Claims-linked chart study.

Subjects: Schizophrenia*/Schizophrenia*/Schizophrenia*/drug therapy ; Schizophrenia*/Schizophrenia*/Schizophrenia*/economics ; Antipsychotic Agents*/Antipsychotic Agents*/Antipsychotic Agents*/economics

  • Source: Journal of managed care & specialty pharmacy [J Manag Care Spec Pharm] 2024 Jul; Vol. 30 (7), pp. 698-709. Date of Electronic Publication: 2024 May 08.Publisher: Academy of Managed Care Pharmacy Country of Publication: United States NLM ID: 101644425 Publication Model: Print-Electronic Cited Medium:

Record details

Read More Add to Saved list
×
Academic Journal

Short-term outcomes of treatment switch to faricimab in patients with aflibercept-resistant neovascular age-related macular degeneration.

  • Authors : Schneider M; Department of Ophthalmology, Rigshospitalet, Valdemar Hansens Vej 1-23, 2600, Glostrup, Denmark. .; Department of Ophthalmology, Semmelweis University, Budapest, Hungary. .

Subjects: Angiogenesis Inhibitors*/Angiogenesis Inhibitors*/Angiogenesis Inhibitors*/administration & dosage ; Drug Substitution* ; Intravitreal Injections*

  • Source: Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie [Graefes Arch Clin Exp Ophthalmol] 2024 Jul; Publisher: Springer-Verlag Country of Publication: Germany NLM ID: 8205248 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Editorial & Opinion

Switching to Interleukin-23 Inhibitors After Ineffectiveness of Ustekinumab: Evaluating Real-World Outcomes in Psoriasis Treatment.

  • Authors : Thomas SE; Department of Dermatology, Radboud University Medical Centre (Radboudumc), Mailbox 9101, 6500 HB, Nijmegen, The Netherlands. .; Seyger MMB

Subjects: Psoriasis*/Psoriasis*/Psoriasis*/drug therapy ; Psoriasis*/Psoriasis*/Psoriasis*/immunology ; Ustekinumab*/Ustekinumab*/Ustekinumab*/therapeutic use

  • Source: American journal of clinical dermatology [Am J Clin Dermatol] 2024 Jul; Vol. 25 (4), pp. 685-688. Date of Electronic Publication: 2024 May 27.Publisher: Adis, Springer International Country of Publication: New Zealand NLM ID: 100895290 Publication Model: Print-Electronic Cited Medium: Internet

Record details

Read More Add to Saved list
×
  • 1-10 of  17,024 results for ""Drug Substitution""